NEWS
Institutional Subscription: Comprehensive Analyses to Enhance Your Global and Local Impact
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Michael Messig
Pfizer Inc. - New York / United States
Others
AD Scientific Index ID: 4387571
-
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Michael Messig's MOST POPULAR ARTICLES
1-)
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goalsDD Waters, C Brotons, CW Chiang, J Ferrières, JA Foody, JW Jukema, ...Circulation 120 (1), 28-34, 20093742009
2-)
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in …H Sillesen, P Amarenco, MG Hennerici, A Callahan, LB Goldstein, J Zivin, ...Stroke 39 (12), 3297-3302, 20083472008
3-)
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor …P Rossignol, D Dobre, JJV McMurray, K Swedberg, H Krum, ...Circulation: Heart Failure 7 (1), 51-58, 20142602014
4-)
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetesDD Waters, JE Ho, SM Boekholdt, DA DeMicco, JJP Kastelein, M Messig, ...Journal of the American College of Cardiology 61 (2), 148-152, 20132602013
5-)
Pharmacokinetics of desipramine coadministered with sertraline or fluoxetineSH Preskorn, J Alderman, M Chung, W Harrison, M Messig, S HarrisJournal of clinical psychopharmacology 14 (2), 90-98, 19942601994
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept